ArticleAmerican journal of translational research2025
Effects of celecoxib combined with glucosamine hydrochloride in the management of knee osteoarthritis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of combination therapy with celecoxib (CEL) and glucosamine hydrochloride (GH) in patients with knee osteoarthritis (KOA).
methodsA total of 115 KOA patients were retrospectively analyzed and divided into a research group that received CEL combined with GH (n=62), while the control group received CEL alone (n=53). Clinical outcomes, safety, pain severity, knee joint function, quality of life (QoL), bone metabolic markers, and inflammatory indicators were assessed and compared between the groups. Factors associated with treatment efficacy were also analyzed.
resultsThe research group showed a significantly higher overall response rate (P=0.018), with no increase in adverse events (P>0.05). Compared to the control group, patients receiving combination therapy experienced greater improvements in pain relief, joint function, QoL, and bone metabolism, along with a more pronounced reduction in inflammatory markers (all P<0.05). Multivariate analysis identified advanced age, alcohol consumption, and smoking history as independent risk factors for poor therapeutic response (all P<0.05).
conclusionsCombination therapy with CEL and GH provides superior clinical benefits for KOA management. However, its efficacy may be reduced in older patients and those with a history of alcohol use or smoking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.